Monovalent type 1 oral poliovirus vaccine in newborns

New England Journal of Medicine

Volumn 359, Issue 16, 2008, Pages 1655-1665

  El Sayed, Nasr ^a   El Gamal, Yehia ^b   Abbassy, Ahmed Amr ^c   Seoud, Iman ^d   Salama, Maha ^e   Kandeel, Amr ^a   Hossny, Elham ^b   Shawky, Ahmed ^c   Hussein, Heba Abou ^d   Pallansch, Mark A ^f   Van Der Avoort, Harrie G A M ^g   Burton, Anthony H ^e   Sreevatsava, Meghana ^e   Malankar, Pradeep ^e   Wahdan, Mohamed H ^e   Sutter, Roland W ^e  

^a MINISTRY OF HEALTH   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

^d Cairo University   (Egypt)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMORAL ANTIBODY; MONOVALENT TYPE 1 ORAL POLIOMYELITIS VACCINE; ORAL POLIOMYELITIS VACCINE; TRIPLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; Z 5181; Z 5285;

ABSENCE OF SIDE EFFECTS; ANTIBODY TITER; ARTICLE; BIRTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EGYPT; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; MALE; NEWBORN; NORMAL HUMAN; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROTYPE; SINGLE DRUG DOSE; VACCINATION; VIRUS EXCRETION; VIRUS SHEDDING;

EID: 54049156876     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0800390     Document Type: Article

References (37)

1. World Health Assembly. Global eradication of poliomyelitis by the year 2000. Resolution WHA 11.28. Geneva: World Health Organization, 1988.
2. World Health Organization. Progress towards interruption of wild poliovirus transmission in 2005. Wkly Epidemiol Rec 2006;81:165-72.
3. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep 2001;50:222-4. [Erratum, MMWR Morb Mortal Wkly Rep 2001;50:249.]
4. World Health Organization. Conclusions and recommendations of the Ad Hoc Advisory Committee on Poliomyelitis Eradication, Geneva, 21-22 September 2004. Wkly Epidemiol Rec 2004;79:401-7.
5. Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991;13:926-39.
6. Swartz TA, Skalska P, Gerichter CG, Cockburn WC. Routine administration of oral polio vaccine in a subtropical area: factors possibly influencing sero-conversion rates. J Hyg (Lond) 1972;70:719-26.
7. John TJ. Problems with oral poliovaccine in India. Indian Pediatr 1972;9:252-6.
8. John TJ, Jayabal P. Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972;96:263-9.
9. Dömök I, Balayan MS, Fayinka OA, Skrtić N, Soneji AD, Harland PS. Factors affecting the efficacy of live poliovirus vaccine in warm climates: efficacy of type 1 Sabin vaccine administered together with antihuman gamma-globulin horse serum to breast-fed and artificially fed infants in Uganda. Bull World Health Organ 1974;51:333-47.
10. Chopra K, Kundu S, Chowdhury DS. Antibody response of infants in tropics to five doses of oral polio vaccine. J Trop Pediatr 1989;35:19-23.
11. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. Am J Epidemiol 1988;128:615-28.
12. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, et al. Live, orally given poliovirus vaccine: effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960;173:1521-6.
13. Posey DL, Linkins RW, Oliveria MJ, Monteiro D, Patriarca PA. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis 1997;175:Suppl 1:S258-S263.
14. Myaux JA, Unicomb L, Besser RE, et al. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996;15:204-9.
15. Bernkopf H, Medalie J, Yekutiel M. Antibodies to poliomyelitis virus and socioeconomic factors influencing their frequency in children in Israel. Am J Trop Med Hyg 1957;6:697-703.
16. Pal SR, Banerjee G, Aikat BK. Serological investigation on endemicity of poliomyelitis in Calcutta and in a neighbouring rural area. Indian J Med Res 1966;54:507-11.
17. Sutter RW, Patriarca PA, Suleiman AJM, et al. Paralytic poliomyelitis in Oman: association between regional differences in attack rate and variations in antibody responses to oral poliovirus vaccine. Int J Epidemiol 1993;22:936-44.
18. Schoub BD, Johnson S, McAnerney J, Gilbertson L, Klaassen KIM, Reinach SG. Monovalent neonatal polio immunization - a strategy for the developing world. J Infect Dis 1988;157:836-9.
19. Lasch EE, Abed Y, Abdulla K, et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984;6:Suppl 2:S467-S470.
20. Bijerk H. Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand 1979;43:195-206.
21. Cáceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after eradication. Clin Infect Dis 2001;33:531-41.
22. Grassly NC, Wenger J, Durrani S, et al. Protective efficacy of a monovalent type 1 oral poliovirus vaccine: a case-control study. Lancet 2007;369:1356-62. [Erratum, Lancet 2007;369:1790.]
23. Expanded Programme on Immunization. Immunization policy. Geneva: World Health Organization, 1996. (WHO/EPI/GEN/95.03 REV 1.)
24. Idem. Product information sheets. Geneva: World Health Organization, 1997. (WHO/EPI/LHIS/97.01.)
25. Albrecht P, Enterline JC, Boone EJ, Klutch MJ. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J Biol Stand 1983;11:91-7.
26. Immunization, vaccines and biologicals. Polio laboratory manual. 4th ed. Geneva: World Health Organization, 2004.
27. R Development Core Team. R: a language and environment for computing. Vienna: R Foundation for Statistical Computing, 2006. (Accessed September 22, 2008, at http://www.R-project.org.)
28. SAS/STAT user's guide, version 6.4. 4th ed. Vol. 1. Cary, NC: SAS Institute, 1989.
29. Conover WJ. Practical nonparametric statistics. New York: John Wiley, 1971.
30. Efron B, Tibshirani R. An introduction to the bootstrap. London: Chapman & Hall, 1993.
31. Robertson HE, Acker MS, Dillenberg HO, et al. Community-wide use of a "balanced" trivalent oral poliovirus vaccine (Sabin): a report of the 1961 trial at Prince Albert, Saskatchewan. Can J Public Health 1962;53:179-91.
32. Horwitz A, Martins da Silva M, Bica AN. Large-scale field studies with live attenuated poliovirus vaccines in the Americas. In: Poliomyelitis: papers and discussions presented at the Fifth International Poliomyelitis Conference. Philadelphia: J.B. Lippincott, 1961:221-7.
33. Smorodintsev AA, Ilyenko VI, Kurnosova MM, Goryev NY, Zhilova GP. Experimental and epidemiological data on the effectiveness of live poliomyelitis vaccine. 2. Virological and immunological characteristics of vaccinal infection in children inoculated per os with a live poliomyelitis vaccine made from the Sabin strains. In: First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1959:313-23. (Scientific publication no. 44.)
34. Voroshilova MK. Influence of dose and schedule of oral immunization of people with live poliovirus vaccine on antibody response. In: Poliomyelitis: papers and discussions presented at the Fifth International Poliomyelitis Conference. Philadelphia: J.B. Lippincott, 1961:296-303.
35. Verlinde JD, Wilterdink JB. A small-scale trial on vaccination and revaccination with live attenuated polioviruses in the Netherlands. In: First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1959:355-66. (Scientific publication no. 44.)
36. Cox HR, Cabasso VJ, Markham PS, et al. Immunologic response to trivalent oral poliomyelitis vaccine. In: First International Conference on Live Poliovirus Vaccines. Washington, DC: Pan American Health Organization, 1959:229-48. (Scientific publication no. 44.)
37. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995;171:1097-106.